Our top pick for
Building a portfolio
Aclaris Therapeutics, Inc is a biotechnology business based in the US. Aclaris Therapeutics shares (ACRS) are listed on the NASDAQ and all prices are listed in US Dollars. Aclaris Therapeutics employs 57 staff and has a trailing 12-month revenue of around USD$6.5 million.
|52-week range||USD$1.02 - USD$30.375|
|50-day moving average||USD$24.5403|
|200-day moving average||USD$12.4685|
|Wall St. target price||USD$29.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-4.168|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$6.5 million|
|Gross profit TTM||USD$-27,989,000|
|Return on assets TTM||-35.87%|
|Return on equity TTM||-95.12%|
|Market capitalisation||USD$1.4 billion|
TTM: trailing 12 months
There are currently 911,063 Aclaris Therapeutics shares held short by investors – that's known as Aclaris Therapeutics's "short interest". This figure is 41.5% up from 643,991 last month.
There are a few different ways that this level of interest in shorting Aclaris Therapeutics shares can be evaluated.
Aclaris Therapeutics's "short interest ratio" (SIR) is the quantity of Aclaris Therapeutics shares currently shorted divided by the average quantity of Aclaris Therapeutics shares traded daily (recently around 619770.74829932). Aclaris Therapeutics's SIR currently stands at 1.47. In other words for every 100,000 Aclaris Therapeutics shares traded daily on the market, roughly 1470 shares are currently held short.
However Aclaris Therapeutics's short interest can also be evaluated against the total number of Aclaris Therapeutics shares, or, against the total number of tradable Aclaris Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aclaris Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Aclaris Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0183% of the tradable shares (for every 100,000 tradable Aclaris Therapeutics shares, roughly 18 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aclaris Therapeutics.
Find out more about how you can short Aclaris Therapeutics stock.
We're not expecting Aclaris Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Aclaris Therapeutics's shares have ranged in value from as little as $1.02 up to $30.375. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aclaris Therapeutics's is 0.7005. This would suggest that Aclaris Therapeutics's shares are less volatile than average (for this exchange).
Aclaris Therapeutics, Inc. , a clinical stage biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. The Company operates in two segments, Therapeutics and Contract Research. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound that is in phase 2 clinical trial for the treatment of moderate to severe rheumatoid arthritis, COVID-19, and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is in phase 2a clinical trial to treat moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound for the treatment for psoriasis and/or inflammatory bowel disease, as well as A-101 45% topical solution to treat common warts. It also provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.